JPRN-UMIN000026143招募中2 期
Phase 2 study of dose-dense nab-paclitaxel followed by EC as neoadjuvant chemotherapy for HER2-negative breast cancer - Phase 2 study of dose-dense nab-paclitaxel followed by EC as neoadjuvant chemotherapy for HER2-negative breast cancer
Teikyo University School of Medicine0 个研究点目标入组 50 人开始时间: 2017年2月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Women who are pregnant or lactating 2) Multiple primary cancer 3) HER2-positive breast cancer 4) Poorly controlled complication (interstitial pneumonia, severe diabetes, heart failure, renal insufficiency, hepatic insufficiency) 5) Active infection 6) Serious peripheral neuropathy (>=CTCAE grade2) 7) Ineligible based on decision of an investigator
研究者
相似试验
尚未招募
2 期
A phase II study of low dose nab-paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancerunresectable or recurrent gastric canceJPRN-UMIN000016196Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine37
已完成
2 期
Phase II study of low-dose Nab-paclitaxel for advanced breast cancerBreast CancerJPRN-UMIN000012048Kitasato University Kitasato Institute Hospital20
已完成
不适用
A phase II study of nab-paclitaxel for pretreated non-small cell lung canceron-small cell lung cancerJPRN-UMIN000012972Kanagawa Cancer Center30
已完成
2 期
A phase 2 study of weekly Nab-Paclitaxel followed by FEC (Fluorouracil, Epirubicin, Cyclophosphamide) as primary therapy for operable breast cancerBreast cancerJPRN-UMIN000007510ahanishi Clinic30
招募中
不适用
Phase II study of weekly Nab-paclitaxel followed by FEC as Neoadjuvant Chemotherapy for Breast CancerBreast cancerJPRN-UMIN000005979Wakayama Medical University50